<DOC>
	<DOCNO>NCT01531348</DOCNO>
	<brief_summary>The purpose study determine feasibility safety adult human bone marrow-derived mesenchymal stem cell intravitreal injection patient retinitis pigmentosa .</brief_summary>
	<brief_title>Feasibility Safety Adult Human Bone Marrow-derived Mesenchymal Stem Cells Intravitreal Injection Patients With Retinitis Pigmentosa</brief_title>
	<detailed_description>Retinitis pigmentosa ( RP ) inherit disorder photoreceptor cell retina . Patients may lose vision since young later life . Currently , 60 gene identify cause condition , one , RPE65 , study several gene therapy trial Leber congenital amaurosis promising result . Another treatment approach RP stem cell therapy . Studies animal model RP show subretinal injection bone marrow-derived mesenchymal stem cell may delay degenerative change photoreceptor cell .</detailed_description>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>Retinitis pigmentosa patient diagnosed ophthalmologist Age 1865 year old Central visual field less equal 20 degree Best correct visual acuity le 6/120 Snellen visual acuity chart Electroretinogram nonrecordable amplitude le 25 % normal Other eye condition could mask interpretation result Unable return follow Underlying disease include asthma , heart failure , myocardial infarction , liver failure , renal failure Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Retinitis pigmentosa</keyword>
	<keyword>Bone marrow-derived mesenchymal stem cell</keyword>
	<keyword>Intravitreal injection</keyword>
</DOC>